Retrovirus Epidemiology Donor Study (REDS) Allogeneic Donor and Recipient Repository (RADAR) - Catalog
Retrovirus Epidemiology Donor Study (REDS) Allogeneic Donor and Recipient Repository (RADAR)
HLB01900909a
REDS-RADAR
RAD
False
False
True
Coded
False
Epidemiology Study
Open BioLINCC Study
Adult
None
2009-10-01
2008-11-18
None
2000-2003
DBDR
Transfusion Medicine
HIV-Related
non-COVID
31921
0
Not Applicable (Specimens Only)
Not Applicable (Specimens Only)
No
Yes
Yes
Yes
Some biospecimens are restricted to research related to transfusion safety and some biospecimens are not restricted.
Acquired Immunodeficiency Syndrome
Blood Donors
Blood Transfusion
HIV Infections
HIV-1
HIV-2
HTLV-I
HTLV-II
Retroviridae Infections
Determine if newly identified or emerging pathogens can be transmitted by transfusion.
Earlier repositories such as the NHLBI-sponsored Transfusion-Transmitted Virus Study (TTVS) and the National Institutes of Health Clinical Center repository were vital to the investigation of viral hepatitis transmission following blood transfusion. Based on the success of these collections it was determined that a more contemporary donor-recipient repository was needed. The Retrovirus Epidemiology Donor Study (REDS) has been conducted since 1989. In the late 1990's it was commissioned to establish a new linked donor-recipient repository.
A total of 127,864 donation specimens were collected from 101,197 different donors. The majority are not linked to any recipient specimens in the repository. The repository contains 13,201 donation specimens from 12,408 donors that were transfused into 3,575 recipients who completed the follow-up visit. Specimens consist of plasma (in most cases) or serum and frozen whole blood samples.
The REDS Allogeneic Donor and Recipient (RADAR) repository was established between 2000 and 2003 by 5 REDS blood centers, 2 CDC-supported blood centers and eight collaborating hospitals with a wide US geographical distribution. Specimens from consented donors were collected, components from their donations were routed to participating hospitals, and recipients of these units consented to provide enrollment and follow-up specimens for long-term storage.
At the time of its completion, RADAR was the largest linked donor-recipient repository in the US. It was designed to be of sufficient size to study the transfusion transmissibility of emerging infectious agents.
Plasma
Serum
Whole Blood
Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3 of the BioLINCC handbook describes the components of the review process
-
Material Types
-
General Freeze/Thaw Status
-
Visits (Vials)
9/27/2016
Serum Plasma Whole Blood Total Pre-Transfusion 1,093 13,071 3,683 17,847 Post-Transfusion 0 6,681 1,558 8,239 6 Month Post Transfusion Follow-Up 0 18,551 3,571 22,122 Donor 0 284,298 127,009 411,307
Last Modified: Sept. 27, 2016, 5:07 p.m. -
Visits (Subjects)
9/27/2016
Serum Total number of subjects Average volume (ml) per subject Pre-Transfusion 595 2.42 Plasma Total number of subjects Average volume (ml) per subject Donor 101,061 3.99 Pre-Transfusion 3,660 2.98 Post-Transfusion 1,556 3.35 6 Month Post Transfusion Follow-Up 3,554 3.16 Whole Blood Total number of subjects Average volume (ml) per subject Donor 100,605 1.83 Pre-Transfusion 3,683 1.52 Post-Transfusion 1,558 1.50 6 Month Post Transfusion Follow-Up 3,570 1.49
Last Modified: Sept. 27, 2016, 5:07 p.m.